Skip to content

Wegovy for heart disease: the approved use, the trial behind it and who pays

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Can you take Wegovy for heart disease? It's FDA-approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. In the label's trial of 17,604 adults, events occurred in 6.5% on Wegovy injection versus 8% on placebo, a hazard ratio of 0.80. CMS, which runs Medicare, says Part D can cover this use.

Source: Wegovy FDA label

Key takeaways

  • Wegovy's heart use is for adults with established cardiovascular disease and either obesity or overweight. Diabetes isn't required.
  • The approved use applies to the injection and the tablets, and it isn't written for people who only have risk factors.
  • Ask your prescriber or cardiologist whether your condition counts as established cardiovascular disease.
  • On Medicare, this use goes through your Part D plan, and you'd not qualify for it under the GLP-1 Bridge.
  • If you already take Ozempic or Rybelsus, your prescriber decides which single medicine fits.

Most people know Wegovy as a weight medicine. Its label also carries a cardiovascular indication, meaning an approved use for the heart and blood vessels. If you have heart disease, that second use can be the difference between a prescription your insurance refuses and one it will consider. This page explains the use, the trial the label reports, how it compares with the heart uses on other GLP-1 labels, and what it means for coverage. The medicine itself is covered in the Wegovy guide.

What the Wegovy label says

The indication reads: to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. It applies to Wegovy injection and Wegovy tablets.

Three parts of that wording do the work:

  • Major adverse cardiovascular events. Often shortened to MACE, this is a combined measure that trials use for serious events such as cardiovascular death, heart attack and stroke.
  • Established cardiovascular disease. The use is for people who already have cardiovascular disease. It isn’t written for people who only have risk factors.
  • Either obesity or overweight. Weight is part of the use. Diabetes isn’t.

“Heart disease” in everyday speech covers many conditions. Whether yours counts as established cardiovascular disease under the label is a question for your prescriber or cardiologist.

What the label trial found

The label reports a cardiovascular outcomes trial of 17,604 adults with a median follow-up of 41.8 months. Its conclusion: “WEGOVY injection significantly reduced the risk for first occurrence of MACE. The estimated hazard ratio (95% CI) was 0.80 (0.72, 0.90).”

In plain numbers, a first major event occurred in 6.5% of patients on Wegovy injection and 8% of patients on placebo (an inactive treatment) over the trial. A hazard ratio of 0.80 compares the rate of events between the two groups across the whole follow-up period. It’s an average over thousands of people and doesn’t tell any one person what will happen to them.

The trial used the injection. The tablets carry the same use on the label.

How other GLP-1 heart indications differ

Four other GLP-1 medicines have a cardiovascular risk reduction use. All four require type 2 diabetes.

  • Ozempic injection. Adults with type 2 diabetes and established cardiovascular disease. In SUSTAIN 6 (3,297 patients, median 2.1 years), the label reports a hazard ratio of 0.74 against placebo, with events in 6.6% versus 8.9%.
  • Ozempic tablets and Rybelsus. Adults with type 2 diabetes who are at high risk for these events. In a trial of 9,650 patients with a median follow-up of about 49.6 months, semaglutide tablets 14 mg gave a hazard ratio of 0.86 against placebo, with events in 12% versus 13.8%.
  • Trulicity. Adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. In the REWIND trial (median follow-up 5.4 years), Trulicity 1.5 mg reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke against placebo, with a hazard ratio of 0.88.
  • Mounjaro. Adults with type 2 diabetes who are at high risk for these events. Its trial compared Mounjaro with dulaglutide, not placebo. Over a median follow-up of 210.1 weeks Mounjaro was non-inferior to dulaglutide, meaning not worse by a set margin, with a hazard ratio of 0.92. The label states that superiority to dulaglutide was not established.

These hazard ratios come from separate trials with different patients, different comparators and different lengths. You can’t line them up to say which medicine protects the heart more, and this site makes no such claim.

Three medicines have no cardiovascular use on their labels: Zepbound, Foundayo and Saxenda. The Saxenda label does report a safety finding from a trial of liraglutide 1.8 mg in 9,340 patients. No increased risk of major adverse cardiovascular events was observed, with events in 13.0% versus 14.9% on placebo. That’s a safety observation on the label, not an approved use.

One investigational medicine, meaning one still being studied, is worth a note because its results have been in the news. In a trial of retatrutide in adults with severe obesity and established cardiovascular disease, Lilly reported fewer cardiovascular events than anticipated in both groups, with a hazard ratio of 0.82 on one pre-specified measure and 1.12 on another. Retatrutide is not FDA-approved for any use. The retatrutide page has the context.

Why this indication matters for coverage

Medicare Part D excludes drugs “when used for” weight loss. CMS’s policy is that an anti-obesity medication is coverable in Part D if it’s used for another medically accepted indication, and its own example is “to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.”

CMS goes further and names Wegovy for this use as coverable under the basic Part D benefit, “regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary.” A formulary is a plan’s list of covered drugs. Plans must follow their existing formulary exception processes for these requests.

Here’s what that means in practice:

  1. The route is your Part D plan. CMS says a person prescribed Wegovy for cardiovascular risk reduction would not qualify for it under the Medicare GLP-1 Bridge. The Bridge is for weight management. Having had a heart attack doesn’t by itself rule out the Bridge, so the reason on the prescription matters. See the Bridge explainer.
  2. Your prescriber documents the cardiovascular disease. Expect a prior authorization (the plan’s approval before it pays) or an exception request.
  3. A negotiated price applies from 2027. CMS and Novo Nordisk agreed a negotiated price of $274 for a 30-day supply of semaglutide for 2027, effective January 1, 2027, and Part D plans must include the selected drugs on their formularies. That’s a price for the drug, not your copay.

The page on whether Medicare covers Wegovy goes through each of these.

Commercial plans set their own criteria. If your plan excludes weight-loss drugs, ask specifically whether it covers Wegovy for the cardiovascular use, and have your prescriber cite the label wording.

What Wegovy costs if coverage fails

Wegovy self-pay through NovoCare starts at $149 a month for the lowest tablet strength, and the 2.4 mg pen is $349 a month. With commercial coverage, the savings offer brings a fill to as little as $25. The Wegovy cost page has every price and the cheapest path tool works from your own situation.

One caution from the label

The Wegovy label says using it with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. If you already take Ozempic or Rybelsus for diabetes, adding Wegovy isn’t what the cardiovascular use describes. Your prescriber decides which single medicine fits.

Frequently asked questions

Is Wegovy FDA-approved for heart disease?

Wegovy is approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. That applies to both the injection and the tablets. It's a risk reduction use for people who already have cardiovascular disease, not a treatment for a heart condition itself.

Does Medicare cover Wegovy for heart disease?

It can. CMS, which runs Medicare, names Wegovy, used to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, as a use coverable under the basic Part D benefit, whether or not the drug is on the plan's formulary (its list of covered drugs). Plans use their formulary exception process for these requests.

Do I need diabetes to get Wegovy for cardiovascular risk?

No. The Wegovy heart use is for adults with established cardiovascular disease and either obesity or overweight, and it doesn't mention diabetes. The cardiovascular uses on the Ozempic, Rybelsus, Trulicity and Mounjaro labels are all for adults with type 2 diabetes.

What did the Wegovy heart trial show?

In the cardiovascular outcomes trial reported on the label, 17,604 adults were followed for a median of 41.8 months. Wegovy injection significantly reduced the risk of a first major adverse cardiovascular event, with an estimated hazard ratio of 0.80. Events occurred in 6.5% of patients on Wegovy and 8% on placebo.

Is Zepbound approved for heart disease?

No. The Zepbound label lists weight reduction and moderate to severe obstructive sleep apnea, and no cardiovascular use. Mounjaro, which also contains tirzepatide, has a cardiovascular risk reduction use for adults with type 2 diabetes at high risk. Each brand has its own label and approved uses.

Sources (17)

  1. 1.
    FDA label (DailyMed): Wegovy prescribing information, section 14.1
    “WEGOVY injection significantly reduced the risk for first occurrence of MACE. The estimated hazard ratio (95% CI) was 0.80 (0.72, 0.90)”
  2. 2.
    FDA label (DailyMed): Ozempic prescribing information, section 14.2
    “OZEMPIC significantly reduced the occurrence of MACE. The estimated hazard ratio for time to first MACE was 0.74 (95% CI: 0.58, 0.95).”
  3. 3.
    FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 14.4
    “Semaglutide tablets significantly reduced the occurrence of MACE. The estimated hazard ratio for time to first MACE was 0.86 (95% CI: 0.77, 0.96) over the median follow-up duration of 49.6 months and 49.4 months for patients randomized to RYBELSUS and placebo, respectively.”
  4. 4.
    FDA label (DailyMed): Trulicity prescribing information, section 14.5
    “TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke (HR: 0.88, 95% CI 0.79, 0.99).”
  5. 5.
    FDA label (DailyMed): Mounjaro prescribing information, section 14.6
    “Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established.”
  6. 6.
    FDA label (DailyMed): Saxenda prescribing information, section 6.1
    “No increased risk for MACE was observed with liraglutide 1.8 mg. The total number of primary component MACE endpoints was 1,302 [608 (13.0%) with liraglutide 1.8 mg and 694 (14.9%) with placebo].”
  7. 7.
    FDA label (DailyMed): Wegovy prescribing information, section 1
    “Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
  8. 8.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  9. 9.
    CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
    “Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
  10. 10.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  11. 11.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
  12. 12.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “These negotiated prices will become effective on January 1, 2027. [...] As required by law, Medicare prescription drug plans, including standalone Part D plans and Medicare Advantage-prescription drug plans, must include in their formularies the selected drugs for which CMS and the participating drug company have agreed to a negotiated price.”
  13. 13.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “In TRIUMPH-3, both studied doses of retatrutide (9 mg and 12 mg) delivered substantial weight loss in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Participants lost up to an average of 55.8 lbs (22.6%) at 80 weeks. In the study, major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms. In pre-specified analyses for time to first occurrence of MACE, there were 44 MACE-5 (all-cause death, heart attack, stroke, heart failure event, or coronary revascularization) events observed in participants randomized to retatrutide (pooled 9 mg and 12 mg) and 52 events observed in those randomized to placebo, resulting in a hazard ratio of 0.82 (95.0% CI: 0.55 to 1.22). There were 27 MACE-3 (cardiovascular death, heart attack, or stroke) events in participants randomized to retatrutide and 23 in those randomized to placebo, resulting in a hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96).”
  14. 14.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use. [...] Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for type 2 diabetes, obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected.”
  15. 15.
  16. 16.
  17. 17.